GALNT11: A Potential Drug Target and Biomarker for Glioblastoma

Target Name: GALNT11

NCBI ID: G63917

GALNT11

GALNT11: A Potential Drug Target and Biomarker for Glioblastoma

Glioblastoma is one of the most aggressive forms of brain cancer, with a poor prognosis and limited treatment options. Despite advances in surgical and radiation therapy, the survival rate for glioblastoma remains high, and the disease is often characterized by the formation of tumors, which can invade and compress surrounding brain tissue.

GALNT11, a gene that encodes a protein known as p-GaNTase 11 (p-GaNTase 11), has been identified as a potential drug target and biomarker for glioblastoma. p-GaNTase 11 is an enzyme that is involved in the degradation of a protein called GLT-1, which is known to promote the formation of tumors.

Studies have shown that p-GaNTase 11 is overexpressed in various types of cancer, including glioblastoma. Overexpression of p-GaNTase 11 has been linked to the development and progression of various cancers, including glioblastoma.

Furthermore, overexpression of p-GaNTase 11 has been shown to enhance the sensitivity of cancer cells to chemotherapy. This is because p-GaNTase 11 helps to regulate the production of the chemotherapy drug, Gemcitabin, leading to a reduction in drug resistance and an increased response to chemotherapy.

GALNT11 has also been shown to play a role in the development of brain metastases, which are a common complication in glioblastoma. Brain metastases are tumors that form in the brain and can cause progressive symptoms, including weakness, vision changes, and difficulty swallowing.

Studies have shown that p-GaNTase 11 is overexpressed in brain metastases and that inhibition of p-GaNTase 11 has the potential to treat brain metastases. This is because p-GaNTase 11 helps to regulate the production of new tumors in the brain, and inhibiting p-GaNTase 11 would reduce the formation of new tumors.

In conclusion, GALNT11 is a potential drug target and biomarker for glioblastoma. Overexpression of p-GaNTase 11 has been linked to the development and progression of various cancers, including glioblastoma, and has also been shown to enhance the sensitivity of cancer cells to chemotherapy and contribute to the development of brain metastases. Further research is needed to determine the effectiveness of targeting p-GaNTase 11 as a potential drug or biomarker for glioblastoma.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 11

Functions: Polypeptide N-acetylgalactosaminyltransferase that catalyzes the initiation of protein O-linked glycosylation and is involved in left/right asymmetry by mediating O-glycosylation of NOTCH1. O-glycosylation of NOTCH1 promotes activation of NOTCH1, modulating the balance between motile and immotile (sensory) cilia at the left-right organiser (LRO). Polypeptide N-acetylgalactosaminyltransferases catalyze the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Displays the same enzyme activity toward MUC1, MUC4, and EA2 than GALNT1. Not involved in glycosylation of erythropoietin (EPO)

The "GALNT11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets